Beijing Wantai Biological Pharmacy Enterprise Future Growth
Future criteria checks 6/6
Beijing Wantai Biological Pharmacy Enterprise is forecast to grow earnings and revenue by 63% and 47.4% per annum respectively. EPS is expected to grow by 58.3% per annum. Return on equity is forecast to be 24.3% in 3 years.
Key information
63.0%
Earnings growth rate
58.3%
EPS growth rate
| Biotechs earnings growth | 34.3% |
| Revenue growth rate | 47.4% |
| Future return on equity | 24.3% |
| Analyst coverage | Low |
| Last updated | 25 Apr 2024 |
Recent future growth updates
Recent updates
Some Investors May Be Willing To Look Past Beijing Wantai Biological Pharmacy Enterprise's (SHSE:603392) Soft Earnings
Apr 04
Things Look Grim For Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) After Today's Downgrade
Apr 02Earnings Tell The Story For Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) As Its Stock Soars 27%
Feb 28Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 14,431 | 5,552 | N/A | N/A | 1 |
| 12/31/2025 | 7,226 | 3,466 | N/A | N/A | 2 |
| 12/31/2024 | 4,844 | 2,553 | N/A | N/A | 2 |
| 3/31/2024 | 3,377 | 128 | 918 | 1,861 | N/A |
| 12/31/2023 | 5,511 | 1,248 | 378 | 1,538 | N/A |
| 9/30/2023 | 7,504 | 2,600 | 1,057 | 1,911 | N/A |
| 6/30/2023 | 9,419 | 3,745 | 1,571 | 2,578 | N/A |
| 3/31/2023 | 10,901 | 4,650 | 2,356 | 3,371 | N/A |
| 12/31/2022 | 11,185 | 4,736 | 3,203 | 4,133 | N/A |
| 9/30/2022 | 10,805 | 4,777 | 2,886 | 4,161 | N/A |
| 6/30/2022 | 9,716 | 3,993 | 1,847 | 3,025 | N/A |
| 3/31/2022 | 8,098 | 3,063 | 887 | 2,053 | N/A |
| 12/31/2021 | 5,750 | 2,021 | 634 | 1,682 | N/A |
| 9/30/2021 | 4,351 | 1,398 | 33 | 888 | N/A |
| 6/30/2021 | 3,475 | 1,155 | 76 | 725 | N/A |
| 3/31/2021 | 2,867 | 896 | 66 | 580 | N/A |
| 12/31/2020 | 2,354 | 677 | 78 | 468 | N/A |
| 9/30/2020 | 1,953 | 551 | 42 | 377 | N/A |
| 6/30/2020 | 1,504 | 368 | 81 | 356 | N/A |
| 3/31/2020 | 1,244 | 239 | 34 | 252 | N/A |
| 12/31/2019 | 1,184 | 209 | 111 | 273 | N/A |
| 9/30/2019 | 1,096 | 217 | 73 | 184 | N/A |
| 6/30/2019 | 1,054 | 269 | 95 | 186 | N/A |
| 3/31/2019 | 1,007 | 279 | -1 | 164 | N/A |
| 12/31/2018 | 983 | 293 | -38 | 208 | N/A |
| 12/31/2017 | 950 | 150 | N/A | 147 | N/A |
| 12/31/2016 | 844 | 148 | N/A | 129 | N/A |
| 12/31/2015 | 681 | 119 | N/A | 152 | N/A |
| 12/31/2014 | 596 | 118 | N/A | 132 | N/A |
| 12/31/2013 | 499 | 80 | N/A | 98 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 603392's forecast earnings growth (63% per year) is above the savings rate (2.9%).
Earnings vs Market: 603392's earnings (63% per year) are forecast to grow faster than the CN market (24.4% per year).
High Growth Earnings: 603392's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 603392's revenue (47.4% per year) is forecast to grow faster than the CN market (14.6% per year).
High Growth Revenue: 603392's revenue (47.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 603392's Return on Equity is forecast to be high in 3 years time (24.3%)